Noninfectious anterior uveitis:
An inflammatory disease of the eye.
Uveitis, in its various forms, is estimated to be responsible for 10% of the blindness in the United States. Anterior uveitis, which occurs in the front of the eye, is the most common form, predominantly occurring in young and middle-aged people.
Our focus at Aldeyra is on noninfectious anterior uveitis, a severe inflammatory ocular disease. Often occurring in conjunction with other autoimmune diseases, it is characterized by pain, sensitivity to light, redness, loss of vision, and other ocular symptoms.
Importantly, uveitis can be considered a model of inflammation. If a drug shows signs of efficacy in uveitis, it may also be efficacious in many other inflammatory diseases.
Current noninfectious anterior uveitis treatment challenges.
Up to now, noninfectious anterior uveitis has typically been treated with topical corticosteroids. However, prolonged use of corticosteroids increases the incidence of cataracts and glaucoma in uveitis. It may also increase the incidence of ocular infection, corneal ulceration, and other toxicities.
The treatment potential of ADX-102.
Anterior uveitis is characterized in part by elevated levels of free aldehydes. ADX-102, Aldeyra’s lead compound, has the potential to mitigate inflammation in uveitis by trapping pro-inflammatory aldehydes. We believe there is a high demand for a novel topical anti-inflammatory agent, to be used in conjunction with or in place of corticosteroids — thereby reducing the burden of corticosteroid use and its associated toxicity.
The prevalence of noninfectious anterior uveitis.
In the United States alone, noninfectious anterior uveitis affects about 25,000 patients annually. Patients with recurrent episodes often develop cataracts, while severe cases may lead to glaucoma and retinal dysfunction.
NONINFECTIOUS ANTERIOR UVEITIS
In the second quarter of 2016, we announced positive data from our Phase II clinical trial of ADX-102 ophthalmic solution in patients with noninfectious anterior uveitis. ADX-102 reduced cell count in a manner comparable to standard-of-care topical corticosteroids, which are effective but toxic, leading to glaucoma and cataracts in many patients.